Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Drug Delivery

News in brief

Merck to build $55m German plant for its allergy business


Allergopharma - a subsidiary of Merck KGaA - building new allergy treatment plant
Allergopharma - a subsidiary of Merck KGaA - building new allergy treatment plant

Merck KGaA subsidiary Allergopharma has begun construction on a €40m ($55m) facility to produce products for type 1 allergies.

The site, in Reinbek near Hamburg, Germany will have an area of more than 6,000m2 containing cleanrooms for production, as well as plant engineering technology, and is being built - in part - to expand production of allergy therapies in new markets, including China.

The firm’s Allergen-specific immunotherapy involves administering increasing doses of allergens with the aim of improving the allergic response and is, according to Allergopharma, the only causal treatment for allergies to unavoidable allergens available.

“We want to fully exploit the potential of our business, whether in Emerging Markets or in rapidly growing and highly promising areas such as the global allergy market,” Stefan Oschmann, a Merck executive board member said.

“With this investment, which is largest in the history of Allergopharma, Merck is setting an important milestone to expand the Allergy business internationally and to secure the future of the Reinbek site.”

The facility is expected to be completed in 2016 and will employ, initially, 40 people.

Related products

Key Industry Events

Interphex 2014

New York, NY 10001 / Conference and exhibition

Read more

Access all events listing